These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 31511088)

  • 21. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
    Int Immunopharmacol; 2024 Aug; 137():112478. PubMed ID: 38901243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.
    Ota Y; Nagai Y; Hirose Y; Hori S; Koga-Yamakawa E; Eguchi K; Sumida K; Murata M; Umehara H; Yamamoto S
    Front Immunol; 2023; 14():1055671. PubMed ID: 36793737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
    Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
    Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
    Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
    J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
    Ma F; Zhang J; Zhang J; Zhang C
    Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
    Siu L; Brody J; Gupta S; Marabelle A; Jimeno A; Munster P; Grilley-Olson J; Rook AH; Hollebecque A; Wong RKS; Welsh JW; Wu Y; Morehouse C; Hamid O; Walcott F; Cooper ZA; Kumar R; Ferté C; Hong DS
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma.
    Zhou Z; Yu X; Zhang J; Tian Z; Zhang C
    Cancer Lett; 2015 Dec; 369(2):298-306. PubMed ID: 26433159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
    Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
    van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
    J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
    Kasturi SP; Rasheed MAU; Havenar-Daughton C; Pham M; Legere T; Sher ZJ; Kovalenkov Y; Gumber S; Huang JY; Gottardo R; Fulp W; Sato A; Sawant S; Stanfield-Oakley S; Yates N; LaBranche C; Alam SM; Tomaras G; Ferrari G; Montefiori D; Wrammert J; Villinger F; Tomai M; Vasilakos J; Fox CB; Reed SG; Haynes BF; Crotty S; Ahmed R; Pulendran B
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32561559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral delivery of TransCon
    Zúñiga LA; Leßmann T; Uppal K; Bisek N; Hong E; Rasmussen CE; Karlsson JJ; Zettler J; Holten-Andersen L; Bang K; Thakar D; Lee YC; Martinez S; Sabharwal SS; Stark S; Faltinger F; Kracker O; Weisbrod S; Müller R; Voigt T; Bigott K; Tabrizifard M; Breinholt VM; Mirza AM; Rosen DB; Sprogøe K; Punnonen J
    Cancer Cell Int; 2022 Sep; 22(1):286. PubMed ID: 36123697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4
    Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
    Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.